SGS Health Science to host a mycoplasma and viral testing webinar

Published: 23-Feb-2024
Manufacturing Contamination Control

It will feature an overview on contamination risks, mycoplasma testing techniques, rapid and culture methods and adventitious virus testing

SGS Health Science have announced their upcoming webinar: “Overcoming contamination risks during biological production: mycoplasma & virus testing”, which is scheduled for March 12, 10:00AM CET. 

In this discussion, Daniel Tatarsky will host a conversation with our SGS colleagues Jean-Jacques Derriche, Sholto Russell and Richard Adair on tracking contaminants in the biomanufacturing process, as per European Pharmacopoeia and USP.

The experts will provide an overview of the latest mycoplasma testing techniques, as well as contamination risks, rapid and culture methods and adventitious viral testing, focusing on both molecular and virology methods.

After the session, there will be a Q&A to answer any queries people may have.

Register here.

 

  • Companies:
  • SGS Health Sciences
See more

You may also like

Manufacturing

SGS to showcase integrated drug development solutions at CPhI, Milan

Read more
Explore SGS’s comprehensive services from analytical testing to clinical research at booth 5D82

Trending Articles

  1. Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its large-scale spray drying unit (GEA PSD-4) at its Boston (MA, US) facility
  2. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  3. Scinai Immunotherapeutics establishes Delaware-based US CDMO subsidiary The biopharmaceutical company now operates contract development and manufacturing services in both Jerusalem and Delaware
  4. Implementing advanced manufacturing technologies for novel therapies Michele Ghinizzini, Senior Vice President, Global Head of Engineering and Maintenance at Sanofi, explores the elements that enable the realistic implementation of advanced technologies in drug development and manufacturing
  5. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

SGS to showcase integrated drug development solutions at CPhI, Milan

Explore SGS’s comprehensive services from analytical testing to clinical research at booth 5D82
Manufacturing

SGS joins forces with Agilex Biolabs

This collaboration marks a significant step in strengthening SGS’s global footprint in the bioanalysis services sector
Manufacturing

SGS recognised as business leader at Scotland’s Life Sciences Awards 2023

In December, SGS committed to increasing its biosafety testing capacity, with a £10 million investment, to support the roll-out of the COVID-19 vaccines throughout 2021 and 2022
Manufacturing

SGS increases biopharmaceutical testing capabilities in Switzerland

The move has expanded the capacity of the laboratory for biologic structural characterisation and offers enhanced identification
Manufacturing

SGS opens testing laboratory in Qingdao

The laboratory’s 45 employees provide a range of direct services with rapid turnaround times
Personal Protection

SGS donates PPE and offers beds and staff to Belgian hospital

Clinical services company’s donated PPE that included 1,100 masks and 21,000 gloves to hospital in Antwerp
Manufacturing

Nitrosamine Detection: meet EMA and FDA regulations

In 2018, the presence of the nitrosamine N-nitrosodimethylamine (NDMA), a potential carcinogen, in certain sartan active pharmaceutical ingredients (APIs) resulted in several regulatory warnings and recalls of contaminated products.
Subscribe now